The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study

Table 1 Patient characteristics

	STF	Non-STF	P Value
	(n = 7)	(n = 6)	P Value
Median Age (range), Years	51 (47–64)	52 (44–69)	1.00
Median Body Mass Index (SEM), kg/m²	25.5 (3.3)	23.8 (2.4)	0.53
WHO-status
Grade 0	6 (85.7 %)	6 (100 %)	0.34
Grade 1	1 (14.3 %)	0 (0.0 %)	0.34
Treatment
Adjuvant	5 (71.4 %)	3 (50.0 %)	0.43
Neo-adjuvant	2 (28.6 %)	3 (50.0 %)	0.43
T-classification
T1	3 (42.9 %)	2 (33.3 %)	0.94
T2	3 (42.9 %)	3 (50.0 %)
T3	1 (14.3 %)	1 (16.7 %)
N-classification
N0	2 (28.6 %)	2 (33.3 %)	0.85
N+	5 (71.4 %)	4 (66.7 %)	0.85
Stage
II	4 (57.2 %)	5 (83.3 %)	0.31
III	3 (42.9 %)	1 (16.7 %)	0.31
ER-status
ER-	1 (14.3 %)	3 (50.0 %)	0.16
ER+	6 (85.7 %)	3 (50.0 %)	0.16
PR-status
PR-	3 (42.9 %)	4 (66.7 %)	0.39
PR+	4 (57.1 %)	2 (33.3 %)	0.39
Grade (BR)
1	1 (14.3 %)	1 (16.7 %)	0.44
2	2 (28.6 %)	4 (66.7 %)
3	3 (42.9 %)	1 (16.7 %)
Unknown	1 (14.3 %)	0 (0.0 %)
Chemotherapy related adjustment
No	3 (42.9 %)	3 (50.0 %)	0.80
Yes	4 (57.1 %)	3 (50.0 %)	0.80

STF short-term fasting, SEM standard error of the mean, ER estrogen receptor; PR progesterone receptor, BR Bloom-Richardson

ISSN: 1471-2407